Last reviewed · How we verify
ZOLIFLODACIN
ZOLIFLODACIN is a Small molecule drug developed by Entasis Therap. It is currently FDA-approved.
Zoliflodacin works by inhibiting bacterial DNA replication.
Zoliflodacin is a small molecule inhibitor of topoisomerase IV, classified as an inhibitor. It has been studied in clinical trials for conditions including gonorrhea and has been tested in healthy volunteers for its safety and tolerability.
At a glance
| Generic name | ZOLIFLODACIN |
|---|---|
| Sponsor | Entasis Therap |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like factories that make copies of themselves. Bacteria are like tiny factories that make copies of themselves too, but zoliflodacin stops them from making these copies by blocking a key enzyme. This helps to slow down or stop the growth of the bacteria, allowing your body to fight off the infection.
Approved indications
Common side effects
- Leukopenia
- Neutropenia
- Headache
- Dizziness
- Nausea
- Diarrhea
Key clinical trials
- Zoliflodacin in Uncomplicated Gonorrhoea (PHASE3)
- Zoliflodacin Bioequivalence and Drug-Drug Interaction Study (PHASE1)
- Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects (PHASE1)
- A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers (PHASE1)
- Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin (PHASE1)
- Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (PHASE2)
- AZD0914 Phase 1 ADME Study in Healthy Volunteers (PHASE1)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914 (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZOLIFLODACIN CI brief — competitive landscape report
- ZOLIFLODACIN updates RSS · CI watch RSS
Frequently asked questions about ZOLIFLODACIN
What is ZOLIFLODACIN?
How does ZOLIFLODACIN work?
Who makes ZOLIFLODACIN?
What development phase is ZOLIFLODACIN in?
What are the side effects of ZOLIFLODACIN?
Related
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing